Company intelligence / Profile preview

Proteostasis Therapeutics

Boston, Massachusetts, United Statesorpha.net ↗

Ownership: Private
Employees: ~17
Development stage: Preclinical

Overview

Proteostasis developed a triple combination therapy for cystic fibrosis that showed positive results in clinical trials. Their lead candidate PTI-428 (CFTR amplifier) demonstrated efficacy in a 28-day Phase 2 study in CF patients on background Orkambi. The company also developed PTI-801 (CFTR corrector) and PTI-808 (CFTR potentiator). In 2020, the company merged with Yumanity Therapeutics, effectively ending its cystic fibrosis drug development efforts.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Cystic Fibrosis Foundation Therapeutics

Beyond the preview

Go deeper on Proteostasis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteostasis Therapeutics.

Explore the full profile